Acasti to Present at the Life Sciences Investor Forum
Acasti to Present at the Life Sciences Investor Forum
PRINCETON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that Prashant Kohli, Chief Executive Officer of Acasti, will present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19th 2024.
新澤西州普林斯頓，2024 年 9 月 12 日（GLOBE NEWSWIRE）—— Acasti Pharma Inc.（納斯達克股票代碼：ACST）（Acasti 或公司）是一家處於後期階段的生物製藥公司，正在推進 GTX-104，其新型可注射的尼莫地平配方可解決罕見疾病動脈瘤性蛛網膜下腔出血（aSaH）的未得到滿足的醫療需求，今天宣佈，Acasti首席執行官普拉尚特·科利將於2024年9月19日在由VirtualInvestorConferences.com主辦的生命科學投資者論壇上現場直播。
譯文內容由第三人軟體翻譯。
